Ionis To Get Head Start On Arrowhead With Tryngolza Launch

 
• By Andrew McConaghie
  
Ionis HQ
Roche will lead the Phase III development of the therapy, based on Ionis' antisense drug platform. • Source: Ionis

More from New Products

More from Scrip